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Sphingomyelin (SM) is one of the major lipid components of
plasma lipoproteins. Serine palmitoyltransferase (SPT) is the
key enzyme in SM biosynthesis. Mice totally lacking in SPT are
embryonic lethal. The liver is the major site for plasma lipopro-
tein biosynthesis, secretion, and degradation, and in this study
we utilized a liver-specific knock-out approach for evaluating
liver SPT activity and also its role in plasma SM and lipoprotein
metabolism. We found that a deficiency of liver-specific Sptlc2
(a subunit of SPT) decreased liver SPT proteinmass and activity
by 95 and 92%, respectively, but had no effect on other tissues.
Liver Sptlc2deficiency decreased plasma SM levels (in both high
density lipoprotein and non-high density lipoprotein fractions)
by 36 and 35% (p< 0.01), respectively, and increased phosphati-
dylcholine levels by 19% (p < 0.05), thus increasing the phos-
phatidylcholine/SM ratio by 77% (p < 0.001), compared with
controls. This deficiency also decreased SM levels in the liver by
38% (p < 0.01) and in the hepatocyte plasmamembranes (based
on a lysenin-mediated cell lysis assay). Liver-specific Sptlc2defi-
ciency significantly increased hepatocyte apoE secretion and
thus increased plasma apoE levels 3.5-fold (p < 0.0001). Fur-
thermore, plasma from Sptlc2 knock-out mice had a signifi-
cantly stronger potential for promoting cholesterol efflux from
macrophages than from wild-type mice (p < 0.01) because of a
greater amount of apoE in the circulation. As a result of these
findings, we believe that the ability to control liver SPT activity
could result in regulation of lipoprotein metabolism and might
have an impact on the development of atherosclerosis.
Sphingomyelin (SM),2 an amphipathic phospholipid located
in the surface monolayer of all classes of plasma lipoproteins
(LDL/very low density lipoprotein, 70–75%;HDL, 25–30%) (1),
has significant effects on lipoprotein metabolism.
A number of studies indicate that plasma SM levels influence
the metabolism of apoB-containing lipoproteins. It has been
reported that SM, but not cholesterol, significantly inhibits trig-
lyceride lipolysis by lipoprotein lipase (2, 3). It has also been
found that SM in lipoproteins delays remnant clearance by
decreasing the binding of apoE to cell membrane receptors (4).
Plasma SM levels also influence high density lipoprotein
(HDL)metabolism.There have been reports that SMaffects the
structure of discoidal and spherical HDL (5). SM can inhibit
lecithin-cholesterol acyltransferase by decreasing its binding to
HDL (6). A negative correlation between the SM content of
HDL and lecithin-cholesterol acyltransferase activity was
observed in studies with proteoliposomes or reconstituted
HDL (7). SM-rich recombinant HDL can inhibit scavenger
receptor class B type I-mediated cholesterol ester-selective
uptake in HepG2 cells (8).
It is known that subendothelial retention and aggregation of
atherogenic lipoproteins play an important role in atherogene-
sis (9). LDL extracted from human atherosclerotic lesions is
highly enriched in SM than in plasma LDL (10–13). LDL
retained in atherosclerotic lesions is acted on by an arterial wall
sphingomyelinase, which promotes aggregation by converting
SM to ceramide (10–12). Sphingomyelinase deficiency dimin-
ishes lipoprotein retention within early atheromata and pre-
vents lesion progression (14). The ratio of SM to PC is increased
5-fold in very low density lipoprotein from hypercholester-
olemic rabbits (15). ApoE knock-out (KO) mice are a well
known atherogenic model. It has been shown that plasma SM
levels in these mice are 4-fold higher than in WT animals (16),
and this may contribute to increased atherosclerosis (17, 18). It
has also been shown that in humans, higher plasma SM levels
and SM/PC ratios are independent risk factors for coronary
heart disease (19, 20). All these data suggest that plasma SM
plays a critical role in the development of atherosclerosis.
The interaction of SM, cholesterol, and glycosphingolipids
drives the formation of plasma membrane rafts (21). These
rafts, formed in the Golgi apparatus, are targeted to the plasma
membranes, where they are thought to exist as islands within
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the sea of bulkmembrane. Although there is disagreement as to
their content, rafts are considered in most reports to include
about 3500 lipid molecules and 30 proteins (22). As much as
65% of the total cellular SM is located in these rafts (23).Manip-
ulation of membrane SM levels by sphingomyelinase can alter
lipid raft composition, thus modifying cell function. For exam-
ple, cholesterol efflux frommacrophage foam cells, a key step in
reverse cholesterol transport, requires trafficking of cholesterol
from intracellular sites to the plasma membranes. Sphingomy-
elinase deficiency decreases cholesterol efflux through promot-
ing cholesterol sequestration by SM (24).
The biochemical synthesis of SM occurs through the actions
of serine palmitoyl-CoA transferase (SPT), 3-ketosphinganine
reductase, ceramide synthase, dihydroceramide desaturase,
and sphingomyelin synthase. Located in the endoplasmic retic-
ulummembranes, SPT is the rate-limiting enzyme in the path-
way (25). Mammalian SPT contains two subunits, Sptlc1 and
Sptlc2, encoding 53- and 63-kDa proteins, respectively (26, 27).
Data from in vivo and in vitro studies suggest that each subunit
is stabilized by forming a dimer (or possibly larger multimer)
with the other (28). Another subunit, Sptlc3, has been reported
(29), and it is important that its functions be further
characterized.
Mice totally lacking Sptlc1 or Sptlc2 are embryonic lethal
(30). Because the liver is the major site for plasma lipoprotein
biosynthesis, secretion, and degradation, we utilized a liver-
specific knock-out approach for evaluating liver SPT activity
and its role in plasma SM and lipoprotein metabolism. We
found that Sptlc2 deficiency in the liver decreases plasma SM
and increases apoE levels.
EXPERIMENTAL PROCEDURES
Reagents
Bovine brain L--phosphatidylcholine (PC), 12-(N-methyl-
N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl))-C6-ceramide, and lys-
enin were purchased from Sigma. [35S]Methionine was from
Amersham Biosciences. WST-1 cell proliferation reagent was
fromRocheApplied Science. The 16:0, 18:0, 20:0, 24:0, and 24:1
ceramides, 17:0 sphingomyelin, and 14:0 phosphatidylcholine
were from Avanti. Labeled 18:0 and 24:0 ceramides were syn-
thesized internally at Eli Lilly and Co. The 15:0 1,3-dipentade-
canoin was from Sigma.
Liver-specific Sptlc2 KO Mouse Preparation
The overall strategy for gene targeting was to delete exon 1
from Sptlc2. Because exon 1 contains the translation codon
ATG, its deletion would be expected to create a null Sptlc2
mouse model.
Sptlc2Flox-FRT Mouse Preparation
Through homologous recombination in mouse embryonic
stem cells (with a C57BL/6 background), we inserted an Loxp
site in the 5-flanking region of the Sptlc2 gene and then a neo-
mycin resistance gene (Neo) cassette, flanking with one pair of
Loxp and one pair of FRT (Fig. 1A), into intron 1. Five positive
clones were identified out of 210 screened (Fig. 1B), and were
injected into blastocysts. Chimeric males were mated withWT
females. Ten heterozygous Sptlc2Flox-FRT mice were obtained
with a C57BL/6 background.
Sptlc2Neo Mouse Preparation
We deleted the Neo cassette by crossing heterozygous
Sptlc2Flox-FRT mice with Flp transgenic ones (Fig. 2A) (31, 32)
from The Jackson Laboratory. We obtained 10 mosaic mice
with Sptlc2Neo (Fig. 2B) and crossed themwithWT animals to
establish 100% heterozygous Sptlc2Neo animals (Fig. 2C).
Sptlc2-flox Mouse Preparation
Heterozygous Sptlc2Neo mice were crossed with each other
(Fig. 2D).
Liver-specific Sptlc2-deficient Mouse Preparation
We injected (intravenously) adeno-associated virus (AAV)-
Cre and AAV-LacZ (2  1011 particles/animal) into 14 Sptlc2-
Flox mice (seven each), according to a published report (33).
One month later, we sacrificed the animals and carried out our
study. During this period, all animals were normal in terms of
FIGURE 1. Sptlc2Flox-FRT mouse preparation. A, strategy for Sptlc2Flox-FRT mouse preparation. An Loxp site was inserted in the 5-flanking region of the Sptlc2
gene. A neomycin-resistant gene (Neo) cassette, flanked with a pair of Loxp sites and a pair of FRT sites, was inserted into intron 1, creating the targeting vector.
A probe complementary to a 330-bp fragment of the gene 3 to the targeting vector was used, first for successfully detecting targeted embryonic stem cells and
subsequently screening for positive mice. B, Southern blot of WT and Sptlc2Flox-FRT mice. The WT mouse has a 7.2-kb PvuII-digested signal; the heterozygous
Flox animal has 7.2- and 8.9-kb signals.
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body weight gain, daily activity, eating, and drinking. We also
carried out lipid analysis 2 months after AAV injection.
Western Blot for Mouse Liver Sptlc1 and Sptlc2
SDS-PAGEwasperformedon4–15%SDS-polyacrylamidegra-
dient gel, using mouse liver homogenate (200 g of protein), and
the separated proteins were transferred to nitrocellulose mem-
brane. Western blot analysis for Sptlc1 was performed, using poly-
clonal anti-mouse Sptlc1 antibody (Pharmingen). Analysis for Sptlc2
was done with polyclonal anti-rabbit Sptlc2 antibody generated by
Proteintech Group, Inc., according to the mouse Sptlc2 peptide
sequence, 536KYSRHRLVPLLDRPFDETTYEETED560.Horseradish
peroxidase-conjugated rabbit polyclonal antibody to mouse IgG
(NovusBiologicals)wasusedasasecondaryantibody forSptlc1, and
horseradishperoxidase-conjugatedgoatpolyclonalantibodytorabbit
IgG (Novus Biologicals) was used for Sptlc2. The SuperSignal West
detectionkit (Pierce)wasused fordetection.Glyceraldehyde-3-phos-
phate dehydrogenase was used as a loading control. The maximum
intensity of each band was measured by Image-Pro Plus version 4.5
software (MediaCybernetics Inc.) andused for analysis.
Tissue SPT Activity Assay
Mouse liver (0.2 g) was homogenized in 0.5 ml of 50 mM
Tris-HCl (pH 7.4), 5 mM EDTA, and 250 mM sucrose. SPT
activity in the homogenates wasmeasured with [14C]serine and
palmitoyl-CoA as substrates, as described previously (30).
Lipid and Lipoprotein Measurements
Fasting plasma was collected for FPLC separation and lipid
measurement. Total cholesterol, phospholipids, and triglycer-
ide in plasma and lipoproteins were assayed by enzymatic
methods (Wako Pure Chemical Industries Ltd., Osaka, Japan).
Plasma SM was measured as described previously (34).
Apolipoprotein Measurement
Plasma apoE, apoB, and apoA-I levels were determined as
described previously (35). Briefly, 0.2 l of plasma were sepa-
rated by 4–15% SDS-gel electrophoresis and immunoblotted
with polyclonal antibodies against apoE (Abcam), apoB (United
States Biological), and apoA-I (Abcam).
FIGURE 2. Liver-specific Sptlc2 KO mouse preparation. A, strategy. A 250-bp fragment was used as a probe for Southern blot analysis. B and C, preparation of
Sptlc2Neo mice. To delete the Neo cassette in the Sptlc2Flox/Frt mice, we crossed heterozygous Sptlc2Flox-FRT animals with Flp transgenic ones. To facilitate screening for
success of the deletion, we designed an internal 250-bp probe for Southern blot analysis. The mosaic (WT  Flox-FRT  Neo) animal has 5.0-, 2.7-, and 0.5-kb signals
(B); and the heterozygous mouse (WT/Flox-FRT) has 5.0- and 2.7-kb EcoRI digested signals (C). D, preparation of Sptlc2-Flox mice. Heterozygous Sptlc2Neo ones were
crossed with each other, thus creating Sptlc2-Flox (homozygous for Sptlc2Neo) animals. E, Sptlc2-Flox mice were injected with AAV-Cre and AAV-LacZ, respectively.
One month later, total genomic DNA was extracted from the liver, and Southern blot was performed to confirm deletion of the Sptlc2 gene. F, Western blot analysis of
Sptlc1 and Sptlc2 in different tissues to indicate liver specificity. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was a loading control. G, liver SPT activity
measurement. These are results from three different animals in both WT and Sptlc2 KO groups. E, EcoRI.
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Lipid Analysis
LC/ESI/MS/MS analysis of sphingolipids was performed,
using a TSQQuantumUltra-triple quadrupolemass spectrom-
eter (Thermo Fisher, San Jose, CA) equipped with an ESI probe
and interfaced with an Agilent 1100 HPLC (Agilent Technolo-
gies, Wilmington, DE). Lipid extracts were separated with an
XBridge C8 (Waters). Mobile phase A was methanol/water/
formic acid (80:20:0.4% by v/v); mobile phase B was methanol/
acetonitrile (50:50% by v/v). Mass spectrometric analyses were
performed on line using electrospray ionization-tandem mass
spectrometry in the positive multiple reaction monitoring
mode. Samples were extracted using the one-phase extraction
method (methanol/chloroform) with internal standards. Cer-
amides, sphingosines, sphingosine 1-phosphate, and dihy-
drosphingosine 1-phosphate levels were quantified by the ratio
of analyte and internal standard and calibration curves
obtained by serial dilution of a mixture of sphingolipids.
Phosphatidylcholine and sphingomyelin levels were meas-
ured by a flow injection ESI-MS/MSmethod, adapted from the
work of Liebisch et al. (36), suitable for rapid monitoring of PC
and SM present at micromoles/liter to millimoles/liter levels in
plasma, tissue, or cell extracts. The flow injection MS/MS sys-
tem consisted of aQuattroUltima triple quadrupolemass spec-
trometer (Waters) interfaced to an 1100 binary HPLC (Agilent
Technologies) and a CTC PAL autosampler (LEAP Technolo-
gies, Carrboro, NC) equipped with an active wash station and
cycle composer control software.
Protonated molecular ions of PC/SM species were selected
by precursor ion scans ofm/z 184, the fragment ion containing
the positively charged phosphocholine lipid headgroup. The
ion intensities across the flow injection profile were summed
together, and after isotope correction, the concentrations of
each PC/SMspecieswere then calculated relative to PC and SM
internal standards, as well as mean response factors obtained
from serial dilution of equimolarmixtures containing 12 differ-
ent PC and 3 SM standards.
Samples (20 l of plasma or 20 mg of tissue homogenate in
deionizedwater) were increased by 5 nmol each of 14:0 PC, 21:0
PC, and 17:0 SM internal standards prior to extraction. Sample
aliquots were diluted into a total of 0.45ml of water, containing
HCl, and 1.5ml of 2:1methanol/chloroform.Aftermixing thor-
oughly, 0.5 ml of water and 0.5 ml of chloroform were added.
The samples were mixed and centrifuged (4000 rpm, 5 °C) for
15min. The chloroform layer was removed, evaporated under a
stream of warm nitrogen, and reconstituted in 1.00 ml of 75%
methanol, 25% chloroform (v/v), 10 mM ammonium acetate,
and 10 l of the lipid extract was analyzed in duplicate/
triplicate.
Lysenin Treatment and Cell Mortality Measurement
Hepatocytes were isolated as described previously (37).
Monolayer cells were washed twice with PBS and incubated
with 200 ng/ml lysenin, or without it as a control, at 37 °C for
2 h. Cellmortalitywasmeasured usingWST-1 cell proliferation
reagent, according to manufacturer’s instructions (Roche
Applied Science). Briefly, WST-1 cell proliferation reagent was
added tomonitor cell mortality. After continuous incubation at
37 °C for 15 min, the solution was transferred to an Eppendorf
tube and spun (12,000 rpm) to pellet cell debris. Supernatant
was then measured by absorbance at 450 nm, a reading for
viable cells.
Cholesterol Efflux
Wild-type macrophages (105 cells/well) were grown in
DMEM with 10% FBS for 24 h to reach a confluency of about
80%. Cell labeling was done by growing the cells overnight in
DMEMwith 10% FBS containing 50 g/ml acetylated LDL and
1 Ci/ml of [3H]cholesterol. Cells were washed three times
with PBS to remove excess label and equilibrated for 2 h with
DMEM without FBS. The medium was replaced with DMEM
containing 10% plasma from WT and liver-specific Sptlc2 KO
mice. We measured [3H]cholesterol radioactivity in the
medium at 4 and 8 h.We alsomeasured radioactivity inside the
cells. The percentage of cholesterol efflux was calculated by
dividing the radioactive amounts in the extracellular media by
the total of the radioactive amounts in the medium and cell
fractions.
Tissue Staining
Hematoxylin and Eosin Staining—All tissues were dissected
out and put into 4% paraformaldehyde for fixation overnight.
Tissues were paraffin-embedded. All tissues were then sliced
(10 m thick). Each slice was deparaffinized and stained with
hematoxylin and eosin according to the standard procedure.
Oil Red O Staining—Frozen liver sections were stained with
Oil Red Oworking solution for 30min. The slides were washed
with water and then stained with hematoxylin solution for
2 min.
X-gal Staining—Liver sections were stained using an X-gal
staining kit (Millipore) according to the manufacturer’s proto-
col. Briefly, frozen liver sections were fixed with cold fixative.
The sectionswerewashed and incubated inX-gal working solu-
tion at 37 °C in the dark for 24 h. They were then rinsed with
PBS and subsequently distilled water. Finally, the sections were
mounted directly with aqueous mounting medium.
-Galactosidase Immunostaining—Frozen liver sections
were incubated with anti--galactosidase antibody (1:500 dilu-
tion) at 4 °C overnight. The sections were washed two times in
Tris/saline buffer for 5min and then incubatedwith fluorescein
isothiocyanate secondary antibody (1:200 dilution) at room
temperature in the dark for 1 h. Again in the dark, sectionswere
washed twice with Tris/saline buffer for 5 min. Finally, they
were examined under a fluorescent microscope.
Primary Hepatocyte Culture and Immunoprecipitation of ApoE
from Culture Medium or Cell Lysate
To investigate the effect of SPT deficiency on apoE secretion,
a pulse-chase experimentwas used in the study.Mouse primary
hepatocytes were isolated and cultured as described previously
(37). Cells were pulse-labeled with [35S]methionine for 30 min
and chased for 1 or 2 h. The newly synthesized apoEwas immu-
noprecipitated from cell homogenates and culturemediumand
analyzed on SDS-PAGE as described previously (37).
StatisticalAnalysis—Each experimentwas conducted at least
five times. Data were typically expressed as mean  S.D. Data
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between two groups were analyzed by Student’s t test. Values
for p of less than 0.05 were considered significant.
RESULTS
Creation of Liver-specific Sptlc2-deficient Mice—To deter-
mine whether an Sptlc2 gene deficiency could be specifically
generated in the liver, we injected (intravenously) AAV-Cre
and AAV-LacZ (2  1011 particles/animal) (Fig. 2A) into 14
Sptlc2-Flox mice (seven each). One month later, we sacrificed
the animals and isolated liver genomic DNA. This was digested
with EcoRI, and an internal 250-bp probe was used to analyze
Southern blots (Fig. 2A). We thus demonstrated that recombi-
nation of the floxed Sptlc2 alleles (and thereby inactivation of
the Sptlc2 gene) could be achieved in essentially 95% of the
hepatocytes after injection of a recombinant AAV carrying the
Cre recombinase (Fig. 2E). Because expression of virally trans-
ferred exogenous genes, in this case the Cre recombinase, is
almost exclusively limited to the liver (33), Sptlc2 inactivation
(95% protein mass) was highly tissue-specific (Fig. 2F). More-
over, Sptlc2 deficiency caused a 92% decrease in liver SPT activ-
ity (Fig. 2G), comparedwith controls, although liver Sptlc1 pro-
tein levels were not significantly affected (Fig. 2F).
To investigate whether liver-specific Sptlc2 KO had any
impact on tissue morphology, we stained sections from the
liver, heart, small intestine, kidney, and lung with hematoxylin
and eosin. As shown in Fig. 3A, neither AAV-Cre nor AAV-
LacZ treatment influenced the morphology of any of these tis-
sues. We also stained the liver section with Oil Red O, and we
found no difference between AAV-Cre- and AAV-LacZ-
treated animals (Fig. 3B). To visualize the efficiency of AAV
infection in the liver, we stained frozen section of the liver with
X-gal and found that the efficiency of AAV-LacZ infection is
roughly 100% (Fig. 3C).We also utilized-galactosidase immu-
nostaining on liver sections, finding that almost all the hepato-
cyteswere stained afterAAV-LacZ infection (Fig. 3D). Thus,we
have created liver-specific SPT KO mice.
Plasma Lipid Analysis in Liver-specific Sptlc2 KO Mice—As
indicated in Table 1, plasma lipid analysis showed a significant
reduction in SM levels of 36% (p  0.001) for both HDL and
non-HDL portions in AAV-Cre-injected mice, compared with
AAV-LacZ-injected animals. To
our surprise, a small but significant
increase of total cholesterol levels in
liver-specific Sptlc2 KO mice was
also observed for both HDL and
non-HDL portions, an increase of
19% (p  0.05). We determined
hydroxymethylglutaryl-CoA reduc-
tase mRNA in the liver using real
time PCR, finding no significant dif-
ference between Sptlc2 KO animals
and controls (data not shown). This
indicated that the plasma choles-
terol increase in Sptlc2KOmicewas
not because of the enhancement of
cholesterol biosynthesis in the liver.
There were no significant changes
in total phospholipid or triglyceride
levels (Table 1).
The distribution of lipids was also
measured by FPLC of pooled plas-
ma samples. This confirmed that
plasma SM levels were significantly
decreased in both HDL and non-
HDL fractions from liver Sptlc2 KO
mice, compared with controls (Fig.
4A). HDL and non-HDL cholesterol
were increased (Fig. 4B), but there
FIGURE 3. Mouse tissue staining. A, liver-specific SPT deficiency changed the morphology of mouse liver,
heart, small intestine, kidney, and lung. The tissue was dissected out and put into 4% paraformaldehyde for
fixation overnight. The tissue was then sliced (10 m thick). Each slice was deparaffinized and stained with
hematoxylin and eosin (H&E). The morphology was checked by microscope. B, Oil Red O staining. C, X-gal
staining. D, -galactosidase immunostaining.
TABLE 1
Plasma lipid measurement in liver-specific Sptlc2 KO and WT mice (enzymatic assay)
Values are as follows: mean  S.D.; n  5. The abbreviations used are as follows: SM, sphingomyelin; Chol, cholesterol; PL, phospholipids; TG, triglyceride; HDL-C, HDL
cholesterol; HDL-PL, HDL phospholipid.
Mice SM HDL-SM Chol HDL-C PL HDL-PL TG
mg/dl mg/dl
WT 25  5 17  4 107  8 86  7 198  17 157  16 47  8
Sptlc2 KO 16  3a 11  3b 126  21b 99  9b 211  27 168  21 50  7
a Values are p  0.01.
b Values are p  0.05.
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were no significant changes in total phospholipid levels
(Fig. 4C).
To determine whether liver Sptlc2 deficiency had any impact
on plasma sphingolipid levels, MS analysis of ceramide, sphin-
gosine, sphingosine 1-phosphate, and dihydroxysphingosine
1-phosphate was performed. As shown in Table 2, plasma SM
levels were again significantly decreased by 36% (p  0.01),
whereas plasma phosphatidylcholine (PC) levels were signifi-
cantly increased by 19% (p  0.01). Thus, the PC/SM ratio was
increased by 77% (p  0.001), compared with controls. More-
over, plasma ceramide levels were also significantly decreased
by 54% (p  0.001), and sphingosine levels were significantly
increased by 35% (p  0.01), whereas there was no change in
sphingosine 1-phosphate and dihydroxysphingosine 1-phos-
phate, compared with controls (Table 2). These results indi-
cated that liver-specific Sptlc2 deficiency inhibited virtually all
liver SPT activity, and dramatically decreased plasma SM levels.
Liver Lipid Analysis in Liver-specific Sptlc2 KO Mice—As
indicated in Table 3, Sptlc2-deficient liver contained significantly
less SM than controls by 38% (p  0.01). Liver Sptlc2 deficiency
also significantly decreased ceramide and sphingosine in the liver
by 39 and 32%, respectively (p 0.01), and increased sphingosine
1-phosphate contents by 38% (p 0.01), comparedwith controls.
There were no significant changes in total cholesterol, phospho-
lipid, or triglyceride levels (data not shown).
We then explored the effect of liver Sptlc2 deficiency on SM
levels in hepatocyte plasma membranes, where the lipid trans-
porters are located and signal transductions are initiated. Lys-
enin is a recently discovered SM-specific cytotoxin (38). Lys-
enin recognizes SM only when it forms aggregates or
microdomains (39). Based on our results above, we anticipated
that Sptlc2 gene deficiency would reduce hepatocyte plasma
membrane SM levels and influence the formation of aggregates
or microdomains that are recognizable by lysenin. To investi-
gate the effect of liver Sptlc2 deficiency on the formation of
these microdomains, we isolated primary hepatocytes from
Sptlc2KO andWTmice, and tested the sensitivity of these cells
to lysenin-mediated cytolysis. As indicated in Fig. 5A, hepato-
cytes lacking in Sptlc2 showed significantly less sensitivity to
lysenin-mediated cytolysis than controls. A dose-dependent
lysenin effect in WT cells was observed, and this effect was
attenuated in Sptlc2 KO hepatocytes (Fig. 5B). We also added
dihydrosphingosine, a precursor of ceramide and SM, to the
cell culture medium and found that there was no significant
difference betweenWTand Sptlc2KOhepatocyteswhen 40M
dihydrosphingosine was used, in terms of their lysenin-medi-
FIGURE 4. Plasma lipoprotein analysis by FPLC in mice. A 200-l aliquot of
pooled plasma (from seven animals) was loaded into a Sepharose 6B column
and eluted with 10 mM Tris and 0.15 M NaCl (pH 7.5). An aliquot of each frac-
tion was used for determination of sphingomyelin. A, total cholesterol. B, total
phospholipids. C, FPLC fast protein liquid chromatography.
TABLE 2
Plasma lipid measurement in liver-specific Sptlc2 KO and WT mice (LC/MS/MS)
Values are as follows: mean  S.D.; n  4–5. The abbreviations used are as follows: SM, sphingomyelin; Cer, ceramide; Sph, sphingosine; S-1-P, sphingosine 1-phosphate;
DHS-1-P, dihydroxysphingosine 1-phosphate.
Mice SM PC PC/SM Cer Sph S-1-P DHS-1-P
M M ng/ml ng/ml ng/ml ng/ml
One month
WT 96  9 1759  97 18  2 1000  85 23  2 264  21 114  14
Sptlc2 KO 61  5a 2096  89a 32  5a 462  42a 31  1a 282  13 99  13
Two months
WT 102  5 1802  117 21  3 912  51 30  4 302  44 123  29
Sptlc2 KO 65  6a 2133  191a 35  9a 501  67a 35  5 297  27 135  39
a Values are p  0.05.
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ated cellmortality (Fig. 5C), indicating that supplement of dihy-
drosphingosine can correct the phenotype caused by Sptlc2
deficiency. These results suggested that liver Sptlc2 deficiency
not only significantly decreased SM levels in the liver, but also
significantly altered the SM-rich microdomains (probably lipid
rafts) in the hepatocyte plasma membranes.
Liver Sptlc2 Deficiency Increases Plasma ApoE Levels—As-
sessment of plasma apolipoprotein levels by reducing SDS-
PAGE revealed a marked increase of apoE, by 3.5-fold (p 
0.0001), but no changes in apoB or apoA-I (Fig. 6,A and B). We
alsomeasured apoE, apoB, and apoA-ImRNA levels in the liver
by real time PCR, finding no significant differences between the
AAV-Cre- and AAV-LacZ-treated mice (data not shown). We
likewise measured liver apoE, apoB, and apoA-I protein levels
(Fig. 6C) and found no changes, indicating that apoE biosynthe-
sis might not be affected.
To examine the effect of SPT deficiency on apoE secretion at
a cellular level, we performed metabolic labeling (pulse-chase)
experiments on primary hepatocytes derived from Sptlc2 KO
andWTmice. There were marked increases in apoE secretion,
2.5-fold at 1 h and 3.3-fold at 2 h (n  4) (p  0.001) from
hepatocytes of AAV-Cre-infected mice, compared with AAV-
LacZ-infected ones (Fig. 7B). In contrast, there was no signifi-
cant difference in apoE accumulation within cells during the
chase (Fig. 7A), indicating that control cells might have higher
rates of intracellular apoE turnover or that Sptlc2-deficient
hepatocytes secrete apoE that is more stable than that from
control hepatocytes. We also incubated the hepatocytes with
different concentration of dihydrosphingosine first and then
measured apoE secretion. We found that there was no signifi-
cant difference between WT and Sptlc2 KO hepatocytes when
40Mdihydrosphingosine was used, in terms of apoE secretion
(Fig. 7C), indicating that supplement of dihydrosphingosine
can correct the phenotype caused by Sptlc2 deficiency.
Plasma from Liver-specific Sptlc2-deficient Mice Promotes
Cholesterol Efflux from Macrophages—Macrophage choles-
terol efflux plays an important role in reverse cholesterol trans-
port, an anti-atherogenic process. Because apoE levels were
increased by 3.5-fold in Sptlc2KOmouse plasma, and apoE is a
well known factor mediating macrophage cholesterol efflux
(40, 41), we speculated that Sptlc2 KO plasma might promote
cholesterol efflux. Thus we investigated the capacity of plasma
from liver-specific Sptlc2-deficient mice tomediate cholesterol
efflux from the mouse macrophage. WT mouse macrophages
derived from bone marrow were labeled with [3H]cholesterol.
Cholesterol efflux was monitored after 10% plasma from either
WT or Sptlc2 KO mice was applied to the macrophages. As
shown in Fig. 8A, Sptlc2KOplasma significantly increased cho-
lesterol efflux from the macrophages, 1.7-fold at 4 h and 2.3-
fold at 8 h, comparedwith plasma fromWTmice (p 0.01). To
investigate the contribution of apoE,which is enriched in Sptlc2
KO plasma, we added recombinant apoE to plasma fromAAV-
LacZ-treated animals prior to assaying for cholesterol efflux,
finding that apoE supplementation (4 g/ml) can significantly
increase cholesterol efflux (Fig. 8B). Furthermore, because
FIGURE 5. Liver-specific Sptlc2 deficiency decreased lysenin-mediated
hepatocyte mortality. Primary hepatocytes were isolated and treated with
lysenin. A, cells were treated with lysenin (200 ng/ml) for 2 h. Cell mortality
was monitored by WST-1 cell proliferation reagent (Roche Applied Science).
B, cells were treated with different concentrations of lysenin for 2 h. C, cells
were treated different concentrations of dihydrosphingosine for 4 h and then
with lysenin (150 ng/ml) for 2 h. Values are mean  S.D., n  5, p  0.01.
TABLE 3
Liver lipid measurement in liver-specific Sptlc2 KO and WT mice (LC/MS/MS)
Values are as follows: mean  S.D.; n  4–5. The abbreviations used are as follows: SM, sphingomyelin; PC, phosphatidylcholine; Cer, ceramide; Sph, sphingosine; S-1-P,
sphingosine-1-phosphate; DHS-1-P, dihydroxysphingosine-1-phosphate.
Mice SM PC Cer Sph S-1-P DHS-1-P
g/mg liver g/mg liver ng/mg liver ng/mg liver ng/mg liver ng/mg liver
One month
WT 0.58  0.02 17  1 134  10 2.2  0.3 0.08  0.01 0.12  0.02
Sptlc2 KO 0.36  0.01a 15  2 82  9a 1.5  0.2a 0.11  0.02a 0.13  0.01
Two months
WT 0.62  0.03 18  2 141  12 1.9  0.2 0.10  0.02 0.15  0.03
Sptlc2 KO 0.39  0.04a 21  4 102  16a 1.6  0.3 0.13  0.01a 0.15  0.01
a Values are p  0.05.
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liver-specific Sptlc2-deficient plasma contains less SM (Table
1), which may also play a role in cholesterol efflux, we supple-
mented plasma from AAV-Cre-treated animals with SM
(20–80mg/dl) and assayed for cholesterol efflux.We found no
significant changes (Fig. 8C), indicating that apoE accumula-
tion, not a decrease in SM, mediates greater cholesterol efflux.
DISCUSSION
In this study, we have demonstrated for the first time that
Cre-Lox system disruption of the Sptlc2 gene in the liver
resulted in the following: 1) loss of
SPT activity in the liver, although
Sptlc1 protein levels were not influ-
enced; 2) significant reduction of
plasma SM and ceramide levels; 3)
significant reduction of liver and
hepatocyte plasma membrane SM
levels; 4) significant increase of
plasma apoE levels in the circula-
tion, but not of apoA-1 and apoB;
and 5) significant increase of choles-
terol efflux from macrophages into
the plasma. Thus, liver-specific SPT
deficiency produces an anti-athero-
genic phenotype in mice.
SM, a phospholipid located in the
surface monolayer of all classes of
plasma lipoproteins (1), has signifi-
cant effects on lipoprotein metabo-
lism. The liver is the major site for
lipoprotein production, and this
study shows that liver SPT, a key
enzyme for SM biosynthesis, con-
tributes roughly 36% to plasma SM
levels (Tables 1 and 2).
We found that higher plasma SM
levels and SM/PC ratios are inde-
pendent risk factors for coronary
heart disease (19, 20). We believe
that LDL retained in atherosclerotic
lesions is acted on by an arterial wall
sphingomyelinase, which promotes
aggregation by converting SM to
ceramide (10–12). There are two
ways of preventing this atherogenic
event, the first being reduction of
sphingomyelinase levels. Indeed, it
has recently been reported that
apoE KO mice lacking in sphingo-
myelinase have decreased develop-
ment of early atherosclerotic lesions
and, more important, decreased
retention of atherogenic lipopro-
teins, compared with apoE KO
matched for similar plasma lipo-
protein levels (14). The second
approach for preventing the athero-
genic event cited above is through
reduction of SM levels in the atherogenic lipoproteins. This can
be done by inhibiting the SMbiosynthesis pathway in the lipopro-
tein-producing tissues, the liver and small intestine. We have
found that liver-specific SPT deficiency can significantly decrease
SM in the circulation. We observed that a liver SPT deficiency
caused a 36% reductionof plasmaSM levels (Table 1 and2). There
are threepossible explanations for ournot observing a larger effect
as follows: 1) there may still have been some residual SPT activity
after AAV-LacZ treatment (Fig. 2G) in the liver; 2) other organs,
for example, the small intestine and lungs, may also make contri-
FIGURE 6. Liver-specific Sptlc2 deficiency significantly increased plasma apoE but not apoB or apoA-I
levels. Plasma apoE, apoB, and apoA-I levels were determined as described previously. Briefly, 0.2 l plasma
was separated by 4 –15% SDS-gel electrophoresis and immunoblotted with polyclonal antibodies against
apoE (Abcam), apoB (United States Biological), and apoA-I (Abcam). A, Western blot of plasma apoA-I, apoB,
and apoE, representative of three independent experiments. B, quantitative display of plasma apolipoproteins.
C, Western blot of apoA-I, apoE, and apoE in mouse livers. Values are mean  S.D., n  5, p  0.001. GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.
FIGURE 7. Sptlc2-deficient hepatocytes secrete more apoE. Primary hepatocytes were labeled with [35S]me-
thionine, and [35S]apoE was immunoprecipitated from cell lysate or media as described under “ Experimental
Procedures.” A, apoE in cell lysates. B, apoE in cell media. C, effect of dihydrosphingosine supplementation.
Primary hepatocytes were first incubated with 0, 20, and 40 M dihydrosphingosine for 4 h and then were used
for apoE secretion. Values are mean  S.D., n  4, p  0.01. Con, control.
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butions to plasma SM levels; and 3) theremay be other factors, for
example sphingomyelinase, that can influence plasma SM levels.
The lysenin experiment indicated that SPT-deficient liver
cells have less SM in the plasmamembranes (Fig. 5). Moreover,
lysenin only recognizes clusters of SM (38, 39), which exist in
microdomains such as lipid rafts. Therefore, an SPT deficiency
may influence lipid raft-mediated events such as cholesterol
efflux (42) and cytokine signaling (NF-B and tumor necrosis
factor- pathways) (43). The relative proportions of both SM
and cholesterol appear critical for raft stability, because deple-
tion of cholesterol or supplementation of the SMpool abolishes
or re-establishes, respectively, detergent insolubility of the
domains and their sorting capacity (44–47).
In this study, we demonstrated that Sptlc2 deficiency
increases plasma apoE (Fig. 6) and increases apoE secretion
from primary hepatocytes (Fig. 7B). It is very likely that SM
reduction alters the structure of cellularmembranes, thus influ-
encing apoE secretion. However, there is another possibility
that changes in ceramide levels may also have an impact on
plasma apoE, because ceramide is one of the components of
large lipid rafts (48, 49). It has been reported that cellular cera-
mide levels are inversely related with apoE secretion frommac-
rophages (50). Decreased ceramide in the livers of Sptlc2 KO
mice (Table 3) might be related to increased apoE secretion.
Details of this process deserve further investigation.
Liver-specific Sptlc2 deficiency causes a small but significant
increase in plasma cholesterol levels (Table 1). This increase is
not related to an increase of liver cholesterol biosynthesis,
because hydroxymethylglutaryl-CoA reductase mRNA levels
do not change (data not shown). It is known that SM is a cho-
lesterol-bindingmolecule (51–53). Based on that, we have spec-
ulated that SPT deficiency promotes cholesterol efflux through
decreasing cellular of cholesterol sequestration by SM. Indeed,
it has been reported that sphingomyelinase-deficient macro-
phages efflux significantly less cholesterol than WT cells, and
this is because of sequestration of cholesterol by SM (24). We
have also observed that Sptlc2 heterozygous KO macrophages
efflux more cholesterol toward apoA-I and HDL.3
We have confirmed a number of previous observations in this
study. For example, we previously reported that homozygous
Sptlc1 or Sptlc2 conventional KOmice are embryonic lethal (30).
In the process of preparing Sptlc2-Flox, we found that the Neo-
resistant genemust be deleted through breeding to Flp transgenic
mice (Fig. 2A) (31, 32). Homozygous Sptlc2-Flox mice cannot be
obtained if theNeo-resistant gene remains in themiddle of intron
1 of the Sptlc2 gene, impeding RNA processing of the gene. It is
known that Sptlc1 and Sptlc2 are subunits of SPT, and both are
essential forSPTactivity (26–28).Thisobservationwasagaincon-
firmed here. We found that Sptlc2 deficiency led to almost com-
plete loss of SPT activity in the liver (Fig. 2G).
In summary, liver-specific SPT deficiency significantly
reduced liver and plasma SM levels and significantly increased
those of plasma apoE. The atheroprotective impact of this find-
ing is currently being evaluated in our laboratory.
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29. Hornemann, T., Richard, S., Rütti, M. F., Wei, Y., and von Eckardstein, A.
(2006) J. Biol. Chem. 281, 37275–37281
30. Hojjati, M. R., Li, Z., and Jiang, X. C. (2005) Biochim. Biophys. Acta 1737,
44–51
31. Farley, F. W., Soriano, P., Steffen, L. S., and Dymecki, S. M. (2000)Genesis
28, 106–110
32. Jones, J. R., Shelton, K. D., and Magnuson, M. A. (2005) Methods Mol.
Med. 103, 245–257
33. Kitajima, K.,Marchadier, D. H.,Miller, G. C., Gao, G. P.,Wilson, J.M., and
Rader, D. J. (2006) Arterioscler. Thromb. Vasc. Biol. 26, 1852–1857
34. Hojjati, M. R., and Jiang, X. C. (2006) J. Lipid Res. 47, 673–676
35. Rohlmann, A., Gotthardt, M., Hammer, R. E., and Herz, J. (1998) J. Clin.
Invest. 101, 689–695
36. Liebisch, G., Lieser, B., Rathenberg, J., Drobnik, W., and Schmitz, G.
(2004) Biochim. Biophys. Acta 1686, 108–117
37. Jiang, X. C., Li, Z., Liu, R., Yang, X. P., Pan,M., Lagrost, L., Fisher, E. A., and
Williams, K. J. (2005) J. Biol. Chem. 280, 18336–18340
38. Yamaji, A., Sekizawa, Y., Emoto, K., Sakuraba, H., Inoue, K., Kobayashi, H.,
and Umeda, M. (1998) J. Biol. Chem. 273, 5300–5306
39. Ishitsuka, R., Yamaji-Hasegawa, A., Makino, A., Hirabayashi, Y., and
Kobayashi, T. (2004) Biophys. J. 86, 296–307
40. Innerarity, T. L., Pitas, R. E., and Mahley, R. W. (1982) Arteriosclerosis 2,
114–124
41. Gordon, V., Innerarity, T. L., andMahley, R.W. (1983) J. Biol. Chem. 258,
6202–6212
42. Landry, Y. D., Denis, M., Nandi, S., Bell, S., Vaughan, A. M., and Zha, X.
(2006) J. Biol. Chem. 281, 36091–36101
43. Hailemariam, T. K., Huan, C., Liu, J., Li, Z., Roman, C., Kalbfeisch,M., Bui,
H. H., Peake, D. A., Kuo, M. S., Cao, G., Wadgaonkar, R., and Jiang, X. C.
(2008) Arterioscler. Thromb. Vasc. Biol. 28, 1519–1526
44. Brown, D. A., and London, E. (2000) J. Biol. Chem. 275, 17221–17224
45. Keller, P., and Simons, K. (1998) J. Cell Biol. 140, 1357–1367
46. Hoekstra, D., and van IJzendoorn, S. C. (2000) Curr. Opin. Cell Biol. 12,
496–502
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